# EDGAR Filing Document

**Accession Number:** 0001885522
**File Stem:** 0001193125-26-161519
**Filing Date:** 2026-4
**Character Count:** 4447
**Document Hash:** 78161c9b8f4902afa8afdb84b6cb2c8c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-161519.hdr.sgml**: 20260417

**ACCESSION NUMBER**: 0001193125-26-161519

**CONFORMED SUBMISSION TYPE**: DEFA14A

**PUBLIC DOCUMENT COUNT**: 3

**FILED AS OF DATE**: 20260417

**DATE AS OF CHANGE**: 20260417

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Neumora Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001885522
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 844367680
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DEFA14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41802
- **FILM NUMBER:** 26871549

**BUSINESS ADDRESS:**
- **STREET 1:** 260 ARSENAL PLACE, SUITE 1
- **CITY:** WATERTOWN
- **STATE:** MA
- **ZIP:** 02472
- **BUSINESS PHONE:** (857) 760-0900

**MAIL ADDRESS:**
- **STREET 1:** 260 ARSENAL PLACE, SUITE 1
- **CITY:** WATERTOWN
- **STATE:** MA
- **ZIP:** 02472

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** RBNC Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20210929

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 14A**

**Proxy Statement Pursuant to Section 14(a) of the<br>Securities Exchange Act of 1934**

**(Amendment No.)**

------

Filed by the Registrant ☒

Filed by a party other than the Registrant ☐

Check the appropriate box:

☐ Preliminary Proxy Statement

☐ **Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))** 

☐ Definitive Proxy Statement

☒ Definitive Additional Materials

☐ Soliciting Material under §240.14a-12

**NEUMORA THERAPEUTICS, INC.**

**(Name of Registrant as Specified In Its Charter)**

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

☒ No fee required.

☐ Fee paid previously with preliminary materials.

☐ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

------

![img13113273_0.jpg](img13113273_0.jpg)

Your vote counts Numora Therapeutics, Inc. 2026 Annual Meeting vote by May 26, 2026 11:59 PM ET. Neumora Therapeutics, INC. 460 Arsenal Street, Suite 1 Watertown, MA 024732 V94606-P52588 you invested in neumora therapeutic's, Inc. and its time to vote! You have the right to vote on proposals being presented at the annual meeting. This is an notice regarding the availability of proxy materials for the stockholder meeting to be held on Monday 27, 2026. Get informed before you vote. View the Notice and Proxy Statement and 10-K online or you can receive a free paper or email copy of the material(s) by requesting prior to may 13, 2026. If you would you like to request a copy of the material (s) for this and/or future stockholder meeting, you may (1) visit www.proxyvote.com, (2) call 1-800-579-1369 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and vote, visit www.proxyvote.com control # smartphone users point your camera here and vote without entering a control number. Vote virtually at the meeting\* May 27, 2026 4:00 PM EDT. \*Please check the meeting materials for any special requirements for meeting attendance.

------

![img13113273_1.jpg](img13113273_1.jpg)

Vote at www.proxyvote.com. This is not a votable Ballot. This is an overview of the proposal being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Voting items 1. To elect three Class III directors to hold until the 2029 annual meeting of stockholder or until their successors are elected: Nominees 1a. Paul Berns For 1b. Matthew Fust For 1c. David Piacquad For 2. To ratify the appointment, by the Audit Committee of the company's Board of Directors, of Ernst & Young LLP, as the independent registered public accounting firm and independent auditor of the company for the year ending December 31, 2026. For. 3. Advisory Vote on the compensation of our named executive officers. For. 4. Advisory vote on the frequency of future advisory on the compensation of our named executive officers. Year Board Recommends prefer to receive an email instead? While voting on www.Proxy vote.com, be sure to click "Delivery Settings".

------